Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses:
Research and development	$ 12,734	$ 13,067
In-process research and development	0	30,393
General and administrative	12,974	14,141
Operating expenses	25,708	57,601
Operating loss	(25,708)	(57,601)
Other income (expense):
Investment income, net	2,724	1,052
Other expense, net	(186)	(155)
Total other income	2,538	897
Net loss before benefit from income taxes and noncontrolling interests	(23,170)	(56,704)
Benefit from income taxes	(2,330)	(2,479)
Net loss	(20,840)	(54,225)
Less - net income (loss) attributable to noncontrolling interests	0	0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders	$ (20,840)	$ (54,225)
Basic and diluted loss per share:
Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share)	$ (2.58)	$ (10.47)
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share)	$ (2.58)	$ (10.47)
Weighted average common shares outstanding:
Basic (in shares)	8,073	5,180
Diluted (in shares)	8,073	5,180